News & Views
Beximco Pharma and Serum Institute of India Announce COVID-19 Vaccine Cooperation
Sep 08 2020 Read 384 Times
Beximco Pharmaceuticals Ltd, the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, and the Serum Institute of India Pvt Ltd (SII), the world’s largest vaccine producer, today announce an agreement in principle for a cooperation and distribution agreement to develop a COVID-19 vaccine, for which Beximco will be the exclusive supplier in Bangladesh.
SII has partnered with AstraZeneca, the Gates Foundation and Gavi, to produce more than a billion doses of a vaccine for global supply. Under the terms of the planned arrangement, Beximco will make a financial contribution to advance the development of the vaccine which will be adjusted based on the vaccine price. SII will prioritise Bangladesh to be one of the first countries to receive an agreed quantity of doses once the vaccine receives all necessary regulatory approvals. Beximco will be the exclusive supplier of the vaccine in Bangladesh and will facilitate the needs of the Government of Bangladesh by offering the opportunity for it to reserve the desired quantities for priority supply at prices to be agreed between the Government and SII. The Company will secure additional quantities of the vaccine to be distributed to the private pay market in Bangladesh. The complexity of the market and production means that any financial implications of this arrangement are difficult to forecast at the current time so the Company will provide the market with any further meaningful updates in due course. The number of doses to be provided to Bangladesh on a priority basis and BPL’s investment amount will be dependent on regulatory approvals, SII’s production capacity and earlier commitments to other countries.
Mr Adar C Poonawalla, CEO of Serum Institute of India and Shayan F Rahman, Principal of Beximco Pharmaceuticals jointly commented: “We are excited to bring together two of the leading pharma companies in India and Bangladesh with the scale and capabilities to bring a hugely promising treatment to the people who need it the most. Between us, we can go a long way towards helping to mitigate the health crisis caused by the COVID-19 pandemic.”
More information online
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Issue Articles - Review of China market shows real potential for lab companies - Biphenyl Modified Silica Stabilised by Bulky Substituents Laboratory Products - ChIP Kits for H...
View all digital editions
Sep 21 2020 Budapest, Hungary
Sep 22 2020 Moscow, Russia
Sep 29 2020 Utrecht, Holland
Oct 06 2020 Lagos, Nigeria
Oct 06 2020 Digital Forum